Pharmaceuticals France

France Antiemetic Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France Antiemetic Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $167.6 Mn Placeholder estimate
Estimate 2025 $172.8 Mn 2.5% of the global market
Projected 2034 $227.5 Mn 31.6% Adds $54.7 Mn over 9 forecast years
CAGR 2025–2034 3.1% Faster than 8% of 183 Pharmaceuticals markets here
Key players 5
  • France is 2.46% of the global market.
  • In Europe, the largest is Germany at $232.0 Mn.
  • Fastest growing: Italy at 3.8% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$54.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Antiemetic Drugs Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $167.6 Mn — —
2025 (base) $172.8 Mn +$5.2 Mn —
2026 (forecast) $178.2 Mn +$5.4 Mn +3.1%
2027 (forecast) $183.7 Mn +$5.5 Mn +6.3%
2028 (forecast) $189.4 Mn +$5.7 Mn +9.6%
2029 (forecast) $195.3 Mn +$5.9 Mn +13%
2030 (forecast) $201.3 Mn +$6.1 Mn +16.5%
2031 (forecast) $207.6 Mn +$6.2 Mn +20.1%
2032 (forecast) $214.0 Mn +$6.4 Mn +23.8%
2033 (forecast) $220.7 Mn +$6.6 Mn +27.7%
2034 (forecast) $227.5 Mn +$6.8 Mn +31.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Antiemetic Drugs Market Analysis at a glance
Market size, 2025$172.8 Mn placeholder estimate
Forecast, 2034$227.5 Mn placeholder estimate
Growth (CAGR), 2025–20343.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersMerck & Co., Inc., Helsinn, Heron Therapeutics, Novartis AG, Eisai Co. (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Antiemetic Drugs Market Analysis Executive Summary

Antiemetic drugs prevent nausea and vomiting from chemotherapy, surgery, pregnancy and motion sickness.

Key segments of the antiemetic Drugs market include drug class (5-HT3 Antagonists, NK1 Antagonists and Dopamine Antagonists) and indication (Chemotherapy-Induced, Post-Operative and Pregnancy).

Bar chart: France Antiemetic Drugs market size, 2024–2034, placeholder estimates. $167.6 Mn in 2024, $172.8 Mn in 2025 and $227.5 Mn in 2034, 3.1% CAGR.
France Antiemetic Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Antiemetic Drugs Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the antiemetic Drugs market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the antiemetic Drugs market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the antiemetic Drugs market.

Competitive Landscape for Antiemetic Drugs Market in France

The antiemetic Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Antiemetic Drugs Market in France

Antiemetic Drugs in France: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antiemetic Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Antiemetic Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Antiemetic Drugs in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 8th highest of the 13 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 12th highest of the 13 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 13 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Inside France

Quick answers

Frequently asked questions

How big is the Antiemetic Drugs market in France?
Placeholder estimate: about $172.8 Mn in 2025, rising to about $227.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Antiemetic Drugs market in France growing?
Placeholder estimate: about 3.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Antiemetic Drugs market report cover?
The report splits the market by drug class (5-HT3 Antagonists, NK1 Antagonists, Dopamine Antagonists, Others), indication (Chemotherapy-Induced, Post-Operative, Pregnancy, Motion Sickness) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Antiemetic Drugs market?
Key players include Merck & Co., Inc., Helsinn, Heron Therapeutics, Novartis AG and Eisai Co..
What is driving the Antiemetic Drugs market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the antiemetic Drugs market.
Who regulates Antiemetic Drugs in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How much research is published on Antiemetic Drugs?
PubMed lists 126 papers on Antiemetic Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on oncology and surgery

See the topic